Journal of Infection最新文献

{"title":"The increasing prevalence of Japanese spotted fever in China: A dominant rickettsial threat","authors":"Zhongqiu Teng , Xue Zhang , Na Zhao, Lupeng Dai, Xianxian Zhang, Ling Han, Tian Qin","doi":"10.1016/j.jinf.2024.106387","DOIUrl":"10.1016/j.jinf.2024.106387","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 2","pages":"Article 106387"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics, risk factors and clinical impact of penicillin and other antibiotic allergies in adults in the UK General Practice: A population-based cohort study","authors":"Yogini H Jani ,&nbsp;Boqing Chen ,&nbsp;Neil Powell ,&nbsp;Philip Howard ,&nbsp;Jonathan Sandoe ,&nbsp;Robert West ,&nbsp;Wallis CY Lau","doi":"10.1016/j.jinf.2024.106367","DOIUrl":"10.1016/j.jinf.2024.106367","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the characteristics, risk factors and clinical impact of penicillin and other antibiotic allergy labels in general practice in the UK.</div></div><div><h3>Design</h3><div>Population-based cohort study.</div></div><div><h3>Setting</h3><div>Primary care in the UK, 2000–2018.</div></div><div><h3>Participants</h3><div>Adults aged 18–100 years who were registered with their general practice for at least 12 months between 01-Jan-2000 and 31-Dec-2018 and followed until 25-Sep-2019.</div></div><div><h3>Main outcome measures</h3><div>The main outcomes include the annual prevalence and incidence of penicillin and other antibiotic allergy labels. Multinominal logistic regression was used to examine the characteristics associated with receiving an allergy label to different antibiotics. Cox regression modelling was used to compare the risk of resistant infections (methicillin-resistant <em>Staphylococcus aureus</em> [MRSA] and vancomycin-resistant enterococci) as well as <em>Clostridioides difficile (C.difficile)</em> infection between patients with and without allergy labels. The monthly proportion of patients who had a penicillin allergy test, either before their allergy label was recorded or within one year, was calculated to assess any impact of NICE penicillin allergy assessment recommendations (Clinical guideline [CG183]) in September 2014.</div></div><div><h3>Results</h3><div>Both the prevalence and incidence of penicillin allergy label showed a pattern of initial growth followed by a decline. The prevalence reached a maximum of 8.25% in 2011, and the incidence peaked at 0.46% in 2004. Older age, being female, living in less deprived areas, belonging to a larger general practice, and having co-morbidities were associated with a higher chance of receiving a penicillin or other antibiotic allergy label. Patients with antibiotic allergy labels were more likely to receive alternative broad-spectrum antibiotics and had a higher risk of MRSA and <em>C.difficile</em> infections. The introduction of NICE drug allergy guideline did not alter the proportion of patients undergoing penicillin allergy assessment.</div></div><div><h3>Conclusion</h3><div>Penicillin and other antibiotic allergy labels are common and lead to radical change in the antibiotic prescribing practices and are associated with resistant and healthcare associated infections.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 2","pages":"Article 106367"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virological characterization of Parvovirus B19 isolated during the atypical 2023-2024 outbreak in France","authors":"Nicolas Veyrenche ,&nbsp;Jacques Fourgeaud ,&nbsp;Marianne Burgard ,&nbsp;Slimane Allali ,&nbsp;Julie Toubiana ,&nbsp;Yaël Pinhas ,&nbsp;Pierre Frange ,&nbsp;Tiffany Guilleminot ,&nbsp;Neil Derridj ,&nbsp;Jérémie F. Cohen ,&nbsp;Marianne Leruez-Ville","doi":"10.1016/j.jinf.2025.106409","DOIUrl":"10.1016/j.jinf.2025.106409","url":null,"abstract":"<div><h3>Background</h3><div>A Parvovirus B19 (B19V) outbreak has been reported in Europe in 2023–2024. The aims of this study were 1) to describe the incidence of primary cases from 2012 to 2024 in one French hospital 2) to analyze the genome of 2023 strains 3) to identify virological profiles according to the clinical presentations of B19V infection.</div></div><div><h3>Methods</h3><div>The incidence of B19V primary cases was studied through an interrupted time-series analysis. Genomes of 2023 strains were sequenced in the NS1-VP1u region. Blood viral loads, IgG and IgM levels were analyzed in 158 cases according to clinical manifestations with Kruskal-Wallis test and a machine learning approach based on k-nearest neighbors.</div></div><div><h3>Results</h3><div>During the 2023–2024 B19V outbreak, there was an 8-time increase in the incidence of B19V infections compared with pre-pandemic levels (8.25 (95%CI: 5.79–11.76)). The 2023 strains belonged to genotype 1a and were closely related to pre-2019 strains. Blood viral loads were significantly different between clinical presentations (p&lt;0.0001). Machine learning allowed us to classify 68.8% (95% CI: 60.9–75.9) patients into the correct clinical group.</div></div><div><h3>Conclusions</h3><div>The 2023–24 epidemic is probably due to the reemergence of the pre-2019 strain. The virological profiles highlighted in this study could assist in accurately interpreting virology results.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 2","pages":"Article 106409"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint blockade in experimental bacterial infections","authors":"Nicole L. Henriksen ,&nbsp;Peter Ø. Jensen ,&nbsp;Louise K. Jensen","doi":"10.1016/j.jinf.2024.106391","DOIUrl":"10.1016/j.jinf.2024.106391","url":null,"abstract":"<div><div>Immune checkpoint inhibitors designed to reinvigorate immune responses suppressed by cancer cells have revolutionized cancer therapy. Similarities in immune dysregulation between cancer and infectious diseases have prompted investigations into the role of immune checkpoints in infectious diseases, including the therapeutic potential of immune checkpoint blockade and drug repurposing. While most research has centered around viral infections, data for bacterial infections are emerging. This systematic review reports on the in vivo effect of immune checkpoint blockade on bacterial burden and selected immune responses in preclinical studies of bacterial infection, aiming to assess if there could be a rationale for using immunotherapy for bacterial infections. Of the 42 analyzed studies, immune checkpoint blockade reduced the bacterial burden in 60% of studies, had no effect in 28% and increased the bacterial burden in 12%. Findings suggest that the effect of immune checkpoint blockade on bacterial burden is context-dependent and in part relates to the pathogen. Further preclinical research is required to understand how the therapeutic effect of immune checkpoint blockade is mediated in different bacterial infections, and if immune checkpoint blockade can be used as an adjuvant to conventional infection management strategies.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 2","pages":"Article 106391"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbial landscape in cerebrospinal fluid of suspected intracranial infections based on clinical metagenomics, a multicentre retrospective study","authors":"Huili Zhou ,&nbsp;Xindie Ren ,&nbsp;Yujing Li ,&nbsp;Caihong Ji ,&nbsp;Xin Wei ,&nbsp;Xiaohan Huang ,&nbsp;Qianqian Wang,&nbsp;Xuan Zhang,&nbsp;Yongpo Jiang,&nbsp;Mingqiang Wang,&nbsp;Hongyu Wang,&nbsp;Nan Wang,&nbsp;Kang Wang,&nbsp;Chao Jiang,&nbsp;Lingtong Huang,&nbsp;Qi Xia","doi":"10.1016/j.jinf.2024.106385","DOIUrl":"10.1016/j.jinf.2024.106385","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 2","pages":"Article 106385"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143317128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical management of human herpesvirus-8-related illnesses in solid organ transplant recipients","authors":"Alessia Dalla Pria ,&nbsp;Ines Ushiro-Lumb ,&nbsp;Mark Bower","doi":"10.1016/j.jinf.2024.106366","DOIUrl":"10.1016/j.jinf.2024.106366","url":null,"abstract":"<div><div>In solid organ transplant recipients (SOTRs), the oncogenic virus human herpesvirus-8 (HHV-8) also named Kaposi sarcoma herpesvirus (KSHV) causes four clinical diseases: Kaposi Sarcoma, Primary Effusion Lymphoma, Multicentric Castleman Disease (MCD), and KSHV inflammatory cytokine syndrome (KICS). This review outlines these clinical scenarios and discusses their management. Although HHV8-related disease in SOTR was first described more than three decades ago, there is a lack of data on treatment so much of the guidance is based on evidence in other immunodeficient patients, particularly people living with HIV. Whilst reduction of immunosuppression and switch from calcineurin inhibitors to mTOR inhibitors may be sufficient in early-stage post-transplant KS, systemic chemotherapy is necessary for advanced-stage KS and in KSHV-related lymphomas. For MCD and KICS, which usually follow primary HHV-8 infection, rituximab-based immunochemotherapy regimens are the cornerstone of treatment for these potentially lethal diseases. Although HHV-8 infection in SOTR is well recognized, it remains under-reported and greater awareness of the different clinical presentations of HHV-8 in this context is fundamental to improve outcomes.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 2","pages":"Article 106366"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the pathogen spectrum of encephalitis/meningitis changing in China?","authors":"Ruichen Wang,&nbsp;Qikai Yin,&nbsp;Kai Nie,&nbsp;Fan Li,&nbsp;Shihong Fu,&nbsp;Qianqian Cui,&nbsp;Han Chen,&nbsp;Songtao Xu,&nbsp;Huanyu Wang","doi":"10.1016/j.jinf.2025.106424","DOIUrl":"10.1016/j.jinf.2025.106424","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 2","pages":"Article 106424"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143025700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of the first unambiguous HIV-1 CRF07_BC/CRF08_BC circulating recombinant form (CRF160_0708) in Yunnan, China","authors":"Min Chen ,&nbsp;Yanling Ma ,&nbsp;Huichao Chen,&nbsp;Jie Dai,&nbsp;Lijuan Dong,&nbsp;Manhong Jia,&nbsp;Wenfei Ding","doi":"10.1016/j.jinf.2024.106383","DOIUrl":"10.1016/j.jinf.2024.106383","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 2","pages":"Article 106383"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distributions of plasmidic genes encoding extended-spectrum and AmpC β-lactamases, and susceptibilities of global non-carbapenemase-producing meropenem-resistant Enterobacterales to ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam-avibactam, 2017–2022","authors":"Shio-Shin Jean ,&nbsp;Hou-Tai Chang ,&nbsp;Chao-Lin Huang ,&nbsp;I.-Min Liu,&nbsp;Po-Chuen Hsieh,&nbsp;Po-Ren Hsueh","doi":"10.1016/j.jinf.2024.106380","DOIUrl":"10.1016/j.jinf.2024.106380","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 2","pages":"Article 106380"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the diagnostic accuracy of Xpert® Mpox and STANDARD™ M10 MPX/OPX for the detection of monkeypox virus","authors":"Alessandra Romero-Ramirez ,&nbsp;Anushri Somasundaran ,&nbsp;Konstantina Kontogianni ,&nbsp;Jacob Parkes ,&nbsp;Yusra Hussain ,&nbsp;Susan Gould ,&nbsp;Christopher T. Williams ,&nbsp;Dominic Wooding ,&nbsp;Richard Body ,&nbsp;Hayley E. Hardwick ,&nbsp;J. Kenneth Baillie ,&nbsp;Jake Dunning ,&nbsp;Malcolm G. Semple ,&nbsp;CONDOR steering group,&nbsp;ISARIC 4C Investigators,&nbsp;Tom E. Fletcher ,&nbsp;Thomas Edwards ,&nbsp;Devy Emperador ,&nbsp;Ana I. Cubas-Atienzar","doi":"10.1016/j.jinf.2025.106413","DOIUrl":"10.1016/j.jinf.2025.106413","url":null,"abstract":"<div><h3>Objectives</h3><div>Evaluation of diagnostic accuracy of two point-of-care (POC) molecular diagnostic tests for the detection of monkeypox virus (MPXV): Xpert® Mpox (Cepheid, Inc., USA) and STANDARD™ M10 MPX/OPX (SD Biosensor, Inc., Korea).</div></div><div><h3>Methods</h3><div>Diagnostic accuracy of both POC platforms was evaluated using 53 upper-respiratory swabs (URS) and 32 skin lesions swabs (SS) collected from mpox and COVID-19 patients in the UK against the Sansure (Sansure Biotech Inc.) and CDC reference qPCR tests. The analytical sensitivity of both platforms was assessed using a viral isolate from II, B.1 lineage.</div></div><div><h3>Results</h3><div>The overall sensitivity and specificity of the Xpert® Mpox was 97.67% [95% CI 87.71–99.94%] and 88.57% [95% CI 73.26–96.80%] and 97.44% [95% CI 86.52–99.94%] and 74.42% [95% CI 58.83–86.48%] comparing the Sansure and CDC qPCR, respectively and for the M10 MPX/OPX was 87.80% [95% CI 73.80–95.92%] and 76.60% [95% CI 61.97–87.70%] and 94.29% [95% CI 80.84–99.30%] and 86.67% [95% CI 73.21–94.95%] with the Sansure and CDC qPCR.</div></div><div><h3>Conclusion</h3><div>The Xpert® Mpox had good diagnostic accuracy for both sample types while the M10 MPX/OPX clinical accuracy was deficient with URS. Our data supports the use of URS during the first 3 days of symptoms onset for mpox diagnosis.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 2","pages":"Article 106413"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}